What are the limitations of the cll ipi?

While the cll ipi is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the cll ipi to ensure safe bedside use and optimal diagnostic accuracy.

How does the cll ipi compare to other Oncology scores?

The cll ipi is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the cll ipi free to use?

Yes. OpiCalc provides the cll ipi completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

CLL-IPI

Haematological Malignancies

Five-factor prognostic index for chronic lymphocytic leukemia using TP53, IGHV, beta-2 microglobulin, stage, and age.

Age

Beta-2 microglobulin

Advanced stage (Binet B/C or Rai I-IV)

IGHV unmutated

TP53 mutation or del(17p)

Waiting For Required Inputs

Complete the required fields to generate the oncology interpretation.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

Baseline prognostic stratification in CLL
Highlights TP53-disrupted and IGHV-unmutated biology

CLINICAL INSIGHT

How it Works

Clinical Inputs

Age

Beta-2 microglobulin

Advanced stage (Binet B/C or Rai I-IV)

IGHV unmutated

TP53 mutation or del(17p)

Interpretive Logic

Age > 65 years adds 1 point.
Advanced clinical stage adds 1 point.
Beta-2 microglobulin > 3.5 mg/L adds 2 points.
IGHV unmutated adds 2 points.
TP53 aberration adds 4 points.

CLINICAL INSIGHT

Practical Pearls

Result Bands

Low

Intermediate

High

Very High

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Use with full staging, cytogenetics, and treatment indication criteria.
Prioritize TP53-aware treatment planning when high-risk biology is present.

CLINICAL INSIGHT

Evidence Base

Five-factor prognostic index for chronic lymphocytic leukemia using TP53, IGHV, beta-2 microglobulin, stage, and age.

OpiCalc Medical Oncology ModuleHaematological Malignancies2026

CLINICAL INSIGHT

Background

Context

CLL-IPI is included in the oncology module as a structured decision-support tool for haematological malignancies workflows.

No clinical reference data available.

CLL-IPI

Haematological Malignancies

Five-factor prognostic index for chronic lymphocytic leukemia using TP53, IGHV, beta-2 microglobulin, stage, and age.

Age

Beta-2 microglobulin

Advanced stage (Binet B/C or Rai I-IV)

IGHV unmutated

TP53 mutation or del(17p)

Waiting For Required Inputs

Complete the required fields to generate the oncology interpretation.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

Baseline prognostic stratification in CLL
Highlights TP53-disrupted and IGHV-unmutated biology

CLINICAL INSIGHT

How it Works

Clinical Inputs

Age

Beta-2 microglobulin

Advanced stage (Binet B/C or Rai I-IV)

IGHV unmutated

TP53 mutation or del(17p)

Interpretive Logic

Age > 65 years adds 1 point.
Advanced clinical stage adds 1 point.
Beta-2 microglobulin > 3.5 mg/L adds 2 points.
IGHV unmutated adds 2 points.
TP53 aberration adds 4 points.

CLINICAL INSIGHT

Practical Pearls

Result Bands

Low

Intermediate

High

Very High

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Use with full staging, cytogenetics, and treatment indication criteria.
Prioritize TP53-aware treatment planning when high-risk biology is present.

CLINICAL INSIGHT

Evidence Base

Five-factor prognostic index for chronic lymphocytic leukemia using TP53, IGHV, beta-2 microglobulin, stage, and age.

OpiCalc Medical Oncology ModuleHaematological Malignancies2026

CLINICAL INSIGHT

Background

Context

CLL-IPI is included in the oncology module as a structured decision-support tool for haematological malignancies workflows.

No clinical reference data available.